Neuroendocrine Tumor
Rohit Gosain, MD; Rahul Gosain, MD, and Pamela Kunz, MD, explore key aspects of neuroendocrine tumor management, from grading classification and molecular profiling through next-generation sequencing to treatment challenges with somatostatin analogues and therapeutic approaches for well-differentiated grade 3 tumors.
EP. 2: Current Challenges With Somatostatin Analogues in Neuroendocrine Tumors
November 14th 2024Panelists discuss how somatostatin analogues, while effective in controlling hormone-related symptoms and tumor growth in neuroendocrine tumors, face challenges including drug resistance, optimal dosing strategies, and timing of initiation in the treatment sequence.
EP. 3: Analyzing Current Therapies for Well-Differentiated Grade 3 Neuroendocrine Tumors
November 14th 2024Panelists discuss how treatment selection for well-differentiated grade 3 neuroendocrine tumors requires careful consideration of factors including Ki-67 index, tumor biology, and disease progression rate to determine whether platinum-based chemotherapy or targeted therapies are most appropriate.
EP. 4: The Role of Next-Generation Sequencing in Patients With Neuroendocrine Tumors
November 14th 2024Panelists discuss how next-generation sequencing can identify actionable mutations and molecular alterations in neuroendocrine tumors, potentially guiding personalized treatment decisions and clinical trial eligibility while advancing our understanding of tumor biology.
